In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells

British Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 739-744

  Depenbrock, H ^a   Peter, R ^a   Faircloth, G T ^b   Manzanares, I ^c   Jimeno, J ^c   Hanauske, A R ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b PharmaMar USA Inc   (United States)

^c PHARMAMAR S A   (Spain)

Author keywords

Aplidine; In vitro activity; Marine anti cancer depsipeptide

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; DEHYDRODIDEMNIN B; DOXORUBICIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER INHIBITION; CLONOGENESIS; DRUG ACTIVITY; EXPLANT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDITERRANEAN SEA; MELANOMA; PRIORITY JOURNAL; TUMOR CELL;

EID: 0031713769     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.570     Document Type: Article

References (24)

1. Auvinen M (1997) Cell transformation, invasion and angiogenesis: a regulatory role for ornithine decarboxylase and polyamines. J Natl Cancer Inst 89: 533-537
2. Bradley TR and Metcalf D (1968) The growth of mouse bone marrow cells in vitro. Aust J Biol Med Sci 46: 335
3. Chun HG, Davies B, Hoth D, Suffness M, Plowman J, Flora K, Grieshaber C and Leyland-Jones B (1986) Didemnin B, the first marine compound entering clinical trials as an antineoplastic agent. Invest New Drugs 4: 279-284
4. Crews CM, Collins JL, Lane WS, Snapper ML and Schreiber SL (1994) GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1a. J Biol Chem 269: 15411-15414
5. Crews CM, Lane WS and Schreiber SL (1996) Didemnin binds to the palmitoyl protein thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci USA 93: 4316-4319
6. Dorr FA, Kuhn JG, Phillips J and Von Hoff DD (1988) Phase I clinical pharmacokinetic investigation of didemnin B, a cyclic depsipeptide. Eur J Cancer Clin Oncol 24: 1699-1706
7. Faircloth G, Perez J, Fernandez JL, Scheuer P, Avila J, Garcia M, Erba E, D'Incalci M, Cañedo V, Garcia D, Garcia De Quesada T and Jimeno J (1995) Marine depsipeptides with activity against solid tumour models. In Proceedings 8th ECCO Congress, Paris, 29 October 2 November. Abstract no. 122, p. 529
8. Faircloth G, Rinehart K, Nuñez de Castro I and Jimeno J (1996) Dehydrodidemnin B a new marine derived antitumour agent with activity against experimental tumour models. Ann Oncol 7: 34
9. Faircloth G, Hanauske A, Depenbroch H, Peter R, Crews C, Manzanares I, Meely K, Grant W and Jimeno J (1997) Preclinical characterization of Aplidine (APD), a new marine anticancer depsipeptide (MADEP). Proc AACR 38(692): 103
10. Geldof AA (1995) Nerve-growth-factor-dependent neurite outgrowth assay: a research model for chemotherapy-induced neuropathy. J Cancer Res Clin Oncol 121: 657-660
11. Gomez-Fabre PM, De Pedro E, Medina MA, Nuñez de Castro I and Marquez J (1997) Polyamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B. Cancer Lett 113: 141-144
12. Hanauske A-R, Hanauske U and Von Hoff DD (1985) The human tumour cloning assay in cancer research and therapy. Curr Probl Cancer 9: 1-50
13. Hanauske U, Hanauske A-R, Marshall MH, Muggia VA and Von Hoff DD (1987) Biphasic effects of vanaduim salts on in vitro tumour colony growth. Int J Cell Cloning 5: 170-178
14. Kucuk O, Young M, Hochster H, Haberman T, Wolf B and Cassileth P (1996) Phase II trial of didemnin B (DDB) in previously treated non-Hodgkin's lymphoma (NHL): an Eastern Cooperative Oncology Group (ECOG) study [ECOG study (Est number 1489)]. Proc ASCO 15: 414
15. Lobo C, García-Pozo SG, Nuñez de Castro I and Alonso FG (1997) Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res 17: 333-336
16. Malfetano JH, Blessing JA and Jacobs AJ (1993) A phase II trial of didemnin B (NSC no. 335319) in patients with previously treated epithelial ovarian cancer Am J Clin Oncol 16: 47-49
17. Malfetano JH, Blessing JA, Homesley HD, Look KY and McGehee R (1996) A phase II trial of didemnin B (NSC no. 335319) in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 19: 184-186
18. Maurer HR and Ali-Osman F (1981) Tumour stem cell cloning in agar-containing capillaries. Naturwiss 68: 381-383
19. Rinehart KL and Lithgow-Bertelloni A (1991) International Patent Wo/81/04985
20. Sakai R, Rinehart KL, Kishore V, Kundu B, Faircloth G, Gloer JB, Carney JR, Namikoshi M, Sun F, Hughes RG, Garcìa Grávalos D, García de Quesada T, Wilson GR and Heid RM (1996) Structure activity relationship of the Didemnins. J Med Chem 39: 2819-2834
21. Shin DM, Holoye PY, Murphy WK, Forman A, Papasozomenos SC, Ki Hong W and Raber M (1991) Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose limiting. Cancer Chemother Pharmacol 29: 145-149
22. Stewart JA, Low JB, Roberts J and Blow A (1991) A phase I clinical trial of didemnin B. Cancer 68: 2550-2554
23. Urdiales JL, Morata P, Núñez De Castro I and Sánchez-Jiménez F (1996) Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 102: 31-37
24. Von Hoff DD, Forseth BJ, Huong M, Buchok JB and Lathan B (1986) Improved plating efficiencies for human tumours cloned in capillary tubes versus petri dishes. Cancer Res 46: 4012-4017